Go Pro

Quest Diagnostics (DGX) 10K Form and Latest SEC Filings 2026

Quest Diagnostics logo
$233.21 -1.09 (-0.47%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$233.06 -0.15 (-0.06%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Quest Diagnostics SEC Filings & Recent Activity

Quest Diagnostics (NYSE:DGX) has submitted 654+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Quest Diagnostics's financial statements. The most recent filing was a Form 4 submitted on July 2, 2026.

Form 4
QUEST DIAGNOSTICS INC Reports Ownership Change on Jul. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Quest Diagnostics Files Quarterly Report on Apr. 22, 2026

The 10-Q contains Quest Diagnostics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Quest Diagnostics SEC Filing History

Browse Quest Diagnostics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/02/2026 3:34 PM
Quest Diagnostics (1022079) Issuer
WENTWORTH TIMOTHY C (1252016) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 3:32 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2026 1:52 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2026 5:38 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 11:26 AM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/21/2026 3:48 PM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/21/2026 3:52 PM
PFEIFFER GARY M (1127304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2026 3:15 PM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 3:15 PM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2026 12:08 PM
Quest Diagnostics (1022079) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 1:39 PM
Quest Diagnostics (1022079) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
04/28/2026 4:22 PM
Quest Diagnostics (1022079) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
04/27/2026 3:17 PM
Quest Diagnostics (1022079) Subject
Form FWP
04/27/2026 7:47 AM
Quest Diagnostics (1022079) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
04/24/2026 5:23 PM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:23 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:23 PM
Lassiter Wright III (1805909) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:23 PM
CARTER ROBERT B (1197607) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:24 PM
Gregg Vicky B (1510304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:24 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:24 PM
Quest Diagnostics (1022079) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:12 PM
Quest Diagnostics (1022079) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/21/2026 5:48 AM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/06/2026 3:32 PM
Quest Diagnostics (1022079) Filer
Form DEF 14A
04/06/2026 3:33 PM
Quest Diagnostics (1022079) Filer
Form DEFA14A
04/02/2026 4:16 PM
Quest Diagnostics (1022079) Issuer
WENTWORTH TIMOTHY C (1252016) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 10:36 AM
Quest Diagnostics (1022079) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/11/2026 5:03 PM
Quest Diagnostics (1022079) Issuer
WENTWORTH TIMOTHY C (1252016) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/11/2026 5:05 PM
Quest Diagnostics (1022079) Issuer
WENTWORTH TIMOTHY C (1252016) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:44 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:44 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:44 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:44 PM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:45 PM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:45 PM
Quest Diagnostics (1022079) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:43 PM
Deppe Michael J (1771759) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 3:43 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 10:53 AM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 9:55 AM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 9:43 AM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2026 3:37 PM
Deppe Michael J (1771759) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
03/04/2026 3:37 PM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:37 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:38 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:38 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:38 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:39 PM
Quest Diagnostics (1022079) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 3:39 PM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2026 11:53 AM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2026 11:12 AM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2026 10:52 AM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/02/2026 1:21 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2026 4:06 PM
Gregg Vicky B (1510304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:07 PM
CARTER ROBERT B (1197607) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:08 PM
Lassiter Wright III (1805909) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:09 PM
Deppe Michael J (1771759) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:10 PM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:10 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:11 PM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:11 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:12 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:12 PM
Quest Diagnostics (1022079) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 4:13 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 9:34 AM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 9:19 AM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2026 9:23 AM
Doherty Catherine T. (1520897) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/10/2026 11:46 AM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/10/2026 5:53 AM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/12/2026 3:37 PM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/28/2025 3:30 PM
Gregg Vicky B (1510304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 3:30 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 3:24 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2025 8:42 AM
Gregg Vicky B (1510304) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 10:02 AM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/07/2025 3:29 PM
Davis J. E. (1599837) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:11 PM
Quest Diagnostics (1022079) Issuer
SAMAD SAM (1694295) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:09 PM
CARTER ROBERT B (1197607) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:09 PM
DELANEY MARK E (1955265) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:10 PM
Gregg Vicky B (1510304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:10 PM
PFEIFFER GARY M (1127304) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:11 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:11 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2025 1:10 PM
PFEIFFER GARY M (1127304) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2025 5:50 AM
Quest Diagnostics (1022079) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/21/2025 5:31 AM
Quest Diagnostics (1022079) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/30/2025 3:36 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/26/2025 3:12 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/25/2025 3:39 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 3:10 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2025 3:14 PM
PREVOZNIK MICHAEL E (1222679) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/25/2025 3:27 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
Your withdrawal order could cost you in taxes (Ad)

If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire.tc pixel

Answer three quick questions to find your advisor match today
08/21/2025 3:34 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 11:10 AM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2025 4:22 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2025 4:25 PM
KUPPUSAMY KARTHIK (1955217) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2025 4:29 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/08/2025 3:40 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2025 12:54 PM
Plewman Patrick (1497368) Reporting
Quest Diagnostics (1022079) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Quest Diagnostics SEC Filings - Frequently Asked Questions

Quest Diagnostics (DGX) has submitted 654+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Quest Diagnostics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Quest Diagnostics's financial statements page.

The most recent filing was a Form 4 submitted on July 2, 2026. This was an insider ownership change filed by 4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:DGX) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners